A Randomized Phase 2 Trial of Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II, and IIIA Non-small Cell Lung Cancer (NSCLC)
Latest Information Update: 09 Jul 2023
At a glance
- Drugs Durvalumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 06 Jun 2023 Results assessing association of circulating CD103+ T cells with major pathological response using peripheral blood mononuclear cells (PBMCs) from study participants presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 27 Dec 2022 Results for safety published in the Journal of Thoracic and Cardiovascular Surgery
- 20 Oct 2022 Status changed from active, no longer recruiting to completed.